The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.

Dave Miller, PhD, discusses how tailored solutions, trust, and lifecycle planning are redefining partnerships in bio/pharmaceutical development.

The scaled adoption of cell and gene therapies demands a new era of agile, precise, and efficient quality control methods.

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Thermoplastic elastomers (TPE) offer a PFAS-free solution for stoppers in parenteral packaging, ensuring a safer and more ...

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Experts from LGM Pharma and Rockwell Automation share their thoughts on what makes tech transfer effective, where processes ...

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...

Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target ...

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...